Collection Sites, LLC is a wholly-owned subsidiary of Medivolve– a publicly traded company that seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19.
Our team is built to search for challenges, develop solutions, and solve the crisis at hand through strategic investment of human and financial resources.
All tests available at Medivolve’s Collection Sites locations are performed by CLIA certified labs and have received an Emergency Use Authorization from the FDA.
1 Patients are eligible for $0 upfront cost if you meet the clinical guidelines for COVID-19 testing. 2 The $99 service fee is for the Rapid Antigen test only. PCR and Rapid Antibody tests are billed to insurance or respective government programs. 3 High demand at labs can delay turnaround times.
Medivolve provides $0 out-of-pocket PCR COVID-19 testing to anyone with recent exposure or symptoms. Patients do not need to pay for expedited PCR testing if there has been a recent exposure. Patients simply need to provide their insurance information or truthfully declare they are uninsured (or undocumented), and the third-party laboratory will bill patient insurance or the Federally funded program, respectively. Patients will not be billed.